Abstract
In January 2020, the FDA approved oral immunotherapy (OIT) for the treatment of peanut allergy in children ages 4 to 17. In June 2020, our clinic began offering FDA-approved peanut OIT with Palforzia. We report the real-world application of FDA-approved peanut OIT at a tertiary care pediatric center.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
